CSIMarket


Terms Beginning with C
       
       
 

Complete Response Letter

Health Care Term


A Complete Response Letter (CRL) is a formal notice issued by the US Food and Drug Administration (FDA) to a drug manufacturer to indicate that the FDA will not approve a New Drug Application (NDA) or a Biologics License Application (BLA) in its current form. The CRL is usually issued after the FDA?s review of the NDA or BLA is complete, and may contain a list of deficiencies that the manufacturer needs to address before the FDA can approve the application.

In the healthcare industry, completing and submitting an NDA or BLA is a critical step in the drug development process, and it requires a significant investment of time, money, and resources. Receiving a CRL can be a setback for a drug manufacturer, as it prolongs the approval process and can delay the drug?s availability on the market.

Drug manufacturers have an opportunity to respond to the deficiencies outlined in the CRL and work with the FDA to address them. This may involve conducting additional studies or providing more data to support the efficacy and safety of the drug. Once the manufacturer has addressed all the issues outlined in the CRL and submitted a satisfactory response, the FDA may approve the NDA or BLA.

Overall, the issuance of a CRL underscores the importance of ensuring that drugs approved for use in the United States are safe and effective, and it highlights the rigorous regulatory framework that governs drug development and approval.


   
     

Complete Response Letter

Health Care Term


A Complete Response Letter (CRL) is a formal notice issued by the US Food and Drug Administration (FDA) to a drug manufacturer to indicate that the FDA will not approve a New Drug Application (NDA) or a Biologics License Application (BLA) in its current form. The CRL is usually issued after the FDA?s review of the NDA or BLA is complete, and may contain a list of deficiencies that the manufacturer needs to address before the FDA can approve the application.

In the healthcare industry, completing and submitting an NDA or BLA is a critical step in the drug development process, and it requires a significant investment of time, money, and resources. Receiving a CRL can be a setback for a drug manufacturer, as it prolongs the approval process and can delay the drug?s availability on the market.

Drug manufacturers have an opportunity to respond to the deficiencies outlined in the CRL and work with the FDA to address them. This may involve conducting additional studies or providing more data to support the efficacy and safety of the drug. Once the manufacturer has addressed all the issues outlined in the CRL and submitted a satisfactory response, the FDA may approve the NDA or BLA.

Overall, the issuance of a CRL underscores the importance of ensuring that drugs approved for use in the United States are safe and effective, and it highlights the rigorous regulatory framework that governs drug development and approval.


Related Health Care Terms
                     
                     
 Adenocarcinoma   Analogues   Arrhythmia  
 Adenosine   ANDA Abbreviated New Drug Application   Arteriosclerosis  
 Adult Stem Cell   Angina   Atherosclerosis  
 Adverse Event   Angiogenesis   Autologous  
 Agonist   Angioplasty   Balloon Angioplasty  
 AIDS   Antagonist   Bioavailability  
 Alkylation Agent   Anti Hypertensive   Biologic Products  
 Allogeneic   Antibody   Biomarker  
 Amino Acid   Antigen   Bradycardia  
 Analgesic   API   Cancer  
               
                  next arrow
 
   


Help

About us

Advertise